AIFF vs BTAI vs INVA vs NRXP

For growth investors, BioXcel Therapeutics, Inc.

(BTAI) is the stronger pick with 64. 2% revenue growth year-over-year, versus -78. 3% for Firefly Neuroscience, Inc. (AIFF). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Innoviva, Inc. (INVA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -99. 7% for BioXcel Therapeutics, Inc. (BTAI). Over 10 years, the gap is even starker: INVA returned +94. 9% versus BTAI's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus BioXcel Therapeutics, Inc. 's 2. 64β — meaning BTAI is approximately 1992% more volatile than INVA relative to the S&P 500.

By revenue growth (latest reported year), BioXcel Therapeutics, Inc.

(BTAI) is pulling ahead at 64. 2% versus -78. 3% for Firefly Neuroscience, Inc. (AIFF). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -384. 8% for Firefly Neuroscience, Inc.. Over a 3-year CAGR, AIFF leads at 50. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -96. 9% for Firefly Neuroscience, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -85. 0% for AIFF. At the gross margin level — before operating expenses — INVA leads at 72. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). BioXcel Therapeutics, Inc. (BTAI) carries a higher beta of 2. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, BTAI: -99. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AIFF (Technology) and BTAI (Healthcare) and INVA (Healthcare) and NRXP (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AIFF is a small-cap quality compounder stock; BTAI is a small-cap high-growth stock; INVA is a small-cap high-growth stock; NRXP is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.